Crinetics Pharmaceuticals to be Acquired by Vertex for $10 Billion in Cash
CRNX has more than doubled off its 52-week low of $25.83 on elevated volume (4.1× avg).
Summary
Crinetics Pharmaceuticals will be acquired by Vertex Pharmaceuticals for $85.00 per share in cash, a deal valued at $10.0 billion, bringing a significant premium to shareholders and integrating Crinetics' key endocrinology drugs into Vertex's portfolio.
Key Events · M&A and Partnerships · CRNX
-
Acquisition Agreement
Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $85.00 per share in cash.
-
Total Transaction Value
The transaction is valued at approximately $10.0 billion in equity, or $8.8 billion net of estimated cash acquired.
-
Significant Shareholder Premium
The offer price of $85.00 per share represents a substantial premium over the company's recent trading price and 52-week high of $57.99.
-
Strategic Asset Integration
The acquisition includes Crinetics' commercialized PALSONIFY for acromegaly and the Phase 3 candidate atumelnant for congenital adrenal hyperplasia, with a combined peak sales potential of over $5 billion.
Analysis · CRNX · Life Sciences
Vertex Pharmaceuticals is acquiring Crinetics Pharmaceuticals for $85.00 per share in cash, representing a significant premium over the company's recent trading price and 52-week high. This acquisition, valued at approximately $10.0 billion in equity, or $8.8 billion net of estimated cash acquired, is a transformational event for Crinetics, providing immediate and certain value to its shareholders. The deal is expected to close in Q3 2026 and will integrate Crinetics' endocrinology assets, including the recently approved PALSONIFY and the Phase 3 atumelnant, into Vertex's portfolio, aiming to accelerate revenue growth and enhance long-term earnings.
At the time of this filing, CRNX was trading at $84.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $25.83 to $57.99. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.